[go: up one dir, main page]

EP0168005B1 - Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant - Google Patents

Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
EP0168005B1
EP0168005B1 EP85108391A EP85108391A EP0168005B1 EP 0168005 B1 EP0168005 B1 EP 0168005B1 EP 85108391 A EP85108391 A EP 85108391A EP 85108391 A EP85108391 A EP 85108391A EP 0168005 B1 EP0168005 B1 EP 0168005B1
Authority
EP
European Patent Office
Prior art keywords
compound
salt
formula
tetrahydropyridine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85108391A
Other languages
German (de)
English (en)
Other versions
EP0168005A3 (en
EP0168005A2 (fr
Inventor
Osamu Nakaguti
Norihiko Shimazaki
Yoshio Kawai
Masashi Hashimoto
Michie Nakatuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848417453A external-priority patent/GB8417453D0/en
Priority claimed from GB858511553A external-priority patent/GB8511553D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AT85108391T priority Critical patent/ATE52089T1/de
Publication of EP0168005A2 publication Critical patent/EP0168005A2/fr
Publication of EP0168005A3 publication Critical patent/EP0168005A3/en
Application granted granted Critical
Publication of EP0168005B1 publication Critical patent/EP0168005B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/26—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • one object of this invention is to provide novel semicarbazide derivatives and a pharmaceutically acceptable salt thereof which are useful as antiinflammatory and analgesic agents.
  • Another object of this invention is to provide processes for preparation of said semicarbazide derivatives and a salt thereof.
  • a further object of this invention is to provide pharmaceutical composition comprising, as an active ingredient, said semicarbazide derivatives and a pharmaceutically acceptable salt thereof.
  • N-substituted-1,2,3,6-tetrahydropyridine derivatives having antiinflammatory and analgesic activities have been known as described, for example, in U.S. Patent 4,088,653 and Journal of Medicinal Chemistry Vol. 25, 720-723, 1982.
  • the object compound [I] and its pharmaceutically acceptable salt can be prepared by the following processes.
  • Suitable pharmaceutically acceptable salt of the object compound [I] is conventional non-toxic salt and includes an organic acid salt [e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate], an inorganic acid salt [e.g. hydrochloride, hydrobromide, sulfate, phosphatej, and a salt with an acidic amino acid [e.g. aspartic acid salt, glutamic acid salt].
  • organic acid salt e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate
  • an inorganic acid salt e.g. hydrochloride, hydrobromide, sulfate, phosphatej
  • a salt with an acidic amino acid e.g. aspartic acid salt, glut
  • the compound [I] and its salt can be prepared by reacting a compound [II] or its salt with a compound [III] or its salt.
  • This reaction is usually carried out in a solvent such as water, methanol, ethanol, dioxane, tetrahydrofuran, benzene, chloroform, methylene chloride or any other organic solvent which does not, adversely influence the reaction.
  • a solvent such as water, methanol, ethanol, dioxane, tetrahydrofuran, benzene, chloroform, methylene chloride or any other organic solvent which does not, adversely influence the reaction.
  • this reaction can be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate], alkali metal carbonate [e.g. sodium carbonate, potassium carbonate], alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, N,N-diisopropyl-N-ethylamine], pyridine compounds [e.g.
  • an alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate
  • alkali metal carbonate e.g. sodium carbonate, potassium carbonate
  • alkaline earth metal carbonate e.g. magnesium carbonate, calcium carbonate
  • tri(lower)alkylamine e.g. trimethylamine, triethylamine, N,N-diisopropyl-N-ethylamine]
  • pyridine compounds
  • N,N-di(lower)alkylaminopyridine such as 4-(N,N-dimethylamino)pyridine], quinoline, N-lower alkylmorphorine [e.g. N-methylmorphorine], and N,N-di(lower)alkylbenzylamine [e.g. N,N-dimethylbenzylamine],.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the compound [I] and its salt can be prepared by reacting a compound [II] or its salt with a compound [IV] or its reactive derivative at the carboxy or hydroxy thiocarbonyl group or a salt thereof.
  • Suitable salts of the compound [II] may be the same as those exemplified for the compounds [I].
  • Suitable reactive derivative at the carboxy or hydroxy thiocarbonyl group of the compound [IV] may include an ester, an acid halide, and an acid anhydride.
  • the suitable examples of the reactive derivatives may be an acid halide [e.g. acid chloride, acid bromide]; a symmetrical acid anhydride; a mixed acid anhydride with an acid such as aliphatic carboxylic acid [e.g. acetic acid, pivalic acid], substituted phosphoric acid [e.g. dialkylphosphoric acid, diphenylphosphoric acid]; an ester such as substituted or unsubstituted lower alkyl ester [e.g.
  • Suitable salts of the compound [IV] and its reactive derivative may include an acid addition salt exemplified for the compounds [I] and a conventional base salt such as an organic base salt [e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'- dibenzylethylenediamine salt], an ammonium salt, an alkali metal salt [e.g. sodium salt, potassium salt], and an alkaline earth metal salt [e.g. calcium salt, magnesium salt].
  • an organic base salt e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'- dibenzylethylenediamine salt
  • an ammonium salt e.g. sodium salt, potassium salt
  • an alkaline earth metal salt e.g. calcium salt, magnesium salt.
  • the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
  • a conventional solvent such as water, acetone, dioxane, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
  • hydrophilic solvents may be used in a mixture with water.
  • the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N' - dicyclohexylcarbodiimide, N - cyclohexyl - N' morphoiinoethyicarbodiimide, N - ethyl - N' - (3 - dimethylaminopropyl)carbodiimide, thionyl chloride, oxalyl chloride, lower alkoxycarbonyl halide [e.g. ethyl chloroformate, isobutyl chloroformate], or 1 - (p - chlorobenzenesulfonyloxy) - 6 - chloro - 1H - benzotriazole,.
  • a conventional condensing agent such as N,N' - dicyclohexylcarbodiimide, N - cyclohexyl - N' morphoiinoethyicarbodiimi
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • the compound [I] and its salt can be prepared by reacting a compound [V] or its reactive derivative at the carboxy or hydroxy thiocarbonyl group or a salt thereof with a compound [VI] or the salt.
  • Suitable reactive derivatives at the carboxy or hydroxy thiocarbonyl group of the compound [V] and suitable salts of the compound [V] and its reactive derivative may be the same as those exemplified for the compound [IV] in the above Process 2.
  • Suitable salts of the compound [VI] may be the same as those exemplified for the compounds [I].
  • reaction can be carried out in substantially the same manner as Process 2, and therefore the reaction mode and reaction conditions [e.g. solvent, condensing agent, reaction temperature] of this reaction are to be referred to those as explained in Process 2.
  • reaction mode and reaction conditions e.g. solvent, condensing agent, reaction temperature
  • the compound [I] obtained by the above processes are isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, or reprecipitation.
  • each of the object compound [I] and the starting compounds [II], [III], [IV], [V], and [VI] may include one or more stereoisomers due to asymmetric carbon atom(s) and/or carbon and carbon double bond (i.e. Z-isomer and E-isomer), and all of such isomers and mixture thereof are included within the scope of this invention.
  • the new semicarbazide derivatives [I] and a pharmaceutically acceptable salt thereof possess antiinflammatory and analgesic activities, and are useful for a therapeutic treatment of inflammation and various pains [e.g. headache, toothache, menorrhalgia].
  • the compound [I] and a pharmaceutically acceptable salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration.
  • a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration.
  • the pharmaceutical preparations may be capsules, tablets, dragees, granules, solution, suspension, or emulsion. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
  • an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound [I] may be effective for treating inflammation and various pains.
  • amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
  • Test A Antiinflammatory activity:
  • Test results Test B (Analgesic activity): (1) Acetic acid induced writhing: (i) Test method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

  1. Procédé pour préparer un composé répondant à la formule:
    Figure imgb0062
    dans lequel
    R2 et R3 forment avec l'atome d'azote auquel ils sont fixés un groupe tétrahydropyridyle, et
    R4 est un groupe pyridyle, éventuellement substitué par un halogène; tétrahydropyridyle; pyrimidinyle; pyrazinyle, ou pyrrolidinyle; et un de ses sels, qui comprend:
    a) le fait de faire réagir un composé répondant à la formule:
    Figure imgb0063
    dans laquelle
    R2 et R3 sont chacun tels que définis ci-dessus, ou un de ses sels, avec un composé répondant à la formule:
    Figure imgb0064
    dans laquelle
    R4 est tel que défini ci-dessus, ou un de ses sels, pour donner un composé répondant à la formule:
    Figure imgb0065
    ou un de ses sels, dans laquelle R2, R3 et R4 sont chacun tels que définis ci-dessus,
    b) le fait de faire réagir un composé répondant à la formule:
    Figure imgb0066
     dans laquelle
    R2 et R3 sont chacun tels que définis ci-dessus, ou un de ses sels, avec un composé répondant à la formule:
    Figure imgb0067
    dans laquelle
    R4 est tel que défini ci-dessus, ou un de ses dérivés réactifs ou un de ses sels, pour donner un composé répondant à la formule:
    Figure imgb0068
    dans laquelle
    R2, R3 et R4 sont chacun tels que définis ci-dessus, ou un de ses sels, ou
    c) le fait de faire réagir un composé répondant à la formule:
    Figure imgb0069
    dans laquelle
    R2 et R3 sont chacun tels que définis ci-dessus, ou un de ses dérivés réactifs ou un de sels sels, avec un composé répondant à la formule:
    Figure imgb0070
    dans laquelle
    R4 est tel que défini ci-dessus, ou un de ses sels, pour donner un composé répondant à la formule:
    Figure imgb0071
    dans laquelle
    R2, R3 et R4 sont chacun tels que définis ci-dessus, ou un de ses sels.
EP85108391A 1984-07-09 1985-07-06 Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant Expired - Lifetime EP0168005B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85108391T ATE52089T1 (de) 1984-07-09 1985-07-06 Semicarbazidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB848417453A GB8417453D0 (en) 1984-07-09 1984-07-09 Semicarbazide derivatives
GB8417453 1984-07-09
GB858511553A GB8511553D0 (en) 1985-05-07 1985-05-07 Semicarbazide derivatives
GB8511553 1985-05-07

Publications (3)

Publication Number Publication Date
EP0168005A2 EP0168005A2 (fr) 1986-01-15
EP0168005A3 EP0168005A3 (en) 1986-12-03
EP0168005B1 true EP0168005B1 (fr) 1990-04-18

Family

ID=26287964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85108391A Expired - Lifetime EP0168005B1 (fr) 1984-07-09 1985-07-06 Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant

Country Status (6)

Country Link
US (1) US4694004A (fr)
EP (1) EP0168005B1 (fr)
CA (1) CA1256434A (fr)
DE (1) DE3577199D1 (fr)
DK (1) DK300085A (fr)
ES (3) ES8609225A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782071A (en) * 1986-11-03 1988-11-01 Warner-Lambert Company Tetrasubstituted urea cholinergic agents
IL137671A0 (en) * 1998-02-04 2001-10-31 Euro Celtique Sa Semicarbazide derivatives and pharmaceutical compositions containing the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001238690A1 (en) * 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
US7087628B2 (en) * 2001-10-04 2006-08-08 Ortho-Mcneil Pharmaceutical, Inc. N-heterocyclyl hydrazides as neurotrophic agents
US20030171411A1 (en) * 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
MXPA05000130A (es) * 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
AU2003248052A1 (en) * 2002-07-12 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperadine derivative
PL1723128T3 (pl) * 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
WO2007006761A1 (fr) * 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoylurées en tant qu’activateurs de glucokinase
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
WO2008084043A1 (fr) * 2007-01-09 2008-07-17 Novo Nordisk A/S Activateurs de la glucokinase à base d'urée
US8318778B2 (en) * 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
EP4487909A3 (fr) 2018-06-12 2025-03-19 vTv Therapeutics LLC Utilisations thérapeutiques d'activateurs de glucokinase en combinaison avec de l'insuline ou des analogues d'insuline
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144853A2 (fr) * 1983-11-21 1985-06-19 Fujisawa Pharmaceutical Co., Ltd. Dérivés semicarbazides, procédé pour leur préparation et compositions pharmaceutiques les contenant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2221812A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von thiosemicarbaziden
BE788313A (fr) * 1972-08-22 1973-03-01 Dainippon Pharmaceutical Co Nouveaux derives 1,3-disubstitues de la thiouree et leur preparation.
US4088653A (en) * 1976-08-23 1978-05-09 Canadian Patents And Developments Limited Tetrahydropyridyl derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144853A2 (fr) * 1983-11-21 1985-06-19 Fujisawa Pharmaceutical Co., Ltd. Dérivés semicarbazides, procédé pour leur préparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
US4694004A (en) 1987-09-15
ES8800142A1 (es) 1987-10-16
EP0168005A3 (en) 1986-12-03
EP0168005A2 (fr) 1986-01-15
ES552537A0 (es) 1987-10-16
CA1256434A (fr) 1989-06-27
ES8800145A1 (es) 1987-11-01
ES8609225A1 (es) 1986-07-16
DE3577199D1 (de) 1990-05-23
ES552536A0 (es) 1987-11-01
ES544963A0 (es) 1986-07-16
DK300085A (da) 1986-01-10
DK300085D0 (da) 1985-07-02

Similar Documents

Publication Publication Date Title
EP0168005B1 (fr) Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant
KR100660309B1 (ko) 시아노페닐 유도체
EP1893609B1 (fr) Derives de n-(pyridin-2-yl)-sulfonamide
AU725403B2 (en) Thrombin inhibitors
US20100137359A1 (en) Caspase inhibitors and uses thereof
HU196990B (en) Process for producing piperazine derivatives with antiarrhythmic effect and pharmaceuticals comprising same
WO2000061556A1 (fr) Composes heterocycliques contenant de l'azote et composes de benamide et medicaments contenant ces composes
US20030229103A1 (en) Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
PT754682E (pt) Derivado de aminostilbazol e medicamento
EP0436734B1 (fr) Nouveaux derives d'aminopiperazine
US5250528A (en) New aminopiperazine derivatives
EP0144853B1 (fr) Dérivés semicarbazides, procédé pour leur préparation et compositions pharmaceutiques les contenant
CN101080392B (zh) 作为抗肥胖药剂的哌嗪基吡啶衍生物
JPWO1991001979A1 (ja) 新規アミノピペラジン誘導体
JP2009519208A (ja) アミド誘導体を含有する医薬組成物
EP0598123A1 (fr) Derive de piperazine et medicament contenant ce derive
KR860000104B1 (ko) 2-피리딘 카복스아미드 유도체의 제조방법
CN113195515A (zh) 新的二肽类化合物及其用途
HU218274B (en) N,n'-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them
US4564621A (en) α-Aryl-α-pyridylalkanoic acid derivatives, process for preparation thereof and pharmaceutical composition comprising the same
US5478945A (en) Thiazoline derivatives
EP1238974B1 (fr) Derivatives heterocycliques et medicaments
JPH05186458A (ja) 新規なベンゾピラン誘導体
EP0126894B1 (fr) Dérivés de troponone, procédés pour leur préparation et composition pharmaceutique les contenant
JPH1135545A (ja) ウレタン誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870523

17Q First examination report despatched

Effective date: 19880812

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19900418

Ref country code: NL

Effective date: 19900418

Ref country code: BE

Effective date: 19900418

Ref country code: AT

Effective date: 19900418

REF Corresponds to:

Ref document number: 52089

Country of ref document: AT

Date of ref document: 19900515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3577199

Country of ref document: DE

Date of ref document: 19900523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19900622

Year of fee payment: 6

ET Fr: translation filed
ITF It: translation for a ep patent filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19900717

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19900726

Year of fee payment: 6

ITTA It: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19900731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19900731

Year of fee payment: 6

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19910706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19910731

Ref country code: CH

Effective date: 19910731

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19920331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19920401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST